Researching the Effect of Aerobic Exercise on Cancer

Running, not enrolling · Not applicable

Conditions studied: Cancer

In brief

This study is being done to answer the following question: Will aerobic exercise (exercise that stimulates and strengthens the heart and lungs, and improves the body's use of oxygen) change the biomarkers (signs of disease) found in the blood?

Key facts

Study ID

NCT03996239

Run by

Memorial Sloan Kettering Cancer Center

People needed

38

Starts

2019-06-20

Expected to finish

2027-06-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cohort 1: CH
• CH called by MSK practices as documented by an MSK physician
• Age ≥18 yrs
• Completion of all anticancer therapy
• High risk of cardiovascular disease defined by presence of at least one of the following:
• Age ≥60
• Prior treatment with chemotherapy
• Prior left-sided breast and/or chest wall radiotherapy
• Currently receiving or previously received androgen deprivation therapy Prior bone marrow transplant
• History of smoking
• Currently treated for one or more cardiovascular risk factors (i.e., hypertension, diabetes, hyperlipidemia)
• Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• Willingness to comply with all study-related procedures
• Cohort 2: Solid Tumor
• Patients at risk of harboring circulating tumor DNA as defined by one of the following:
• Histologically confirmed stage III (i.e., high risk of recurrence) colorectal cancer within 2 years of completion of all adjuvant therapy.
• Histologically confirmed stage III breast cancer with residual disease after neoadjuvant therapy and within 12 months of completing (neo)adjuvant chemotherapy
• Patients with metastatic breast cancer and radiographic stable disease or NED for ≥6 months and not currently receiving chemotherapy (endocrine therapy and anti-HER2 antibodies allowed)
• Age ≥ 18 yrs
• Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
• Willingness to comply with all study-related procedures
• Cohort 3: Active Surveillance
• Men with histologically confirmed localized prostate cancer undergoing active surveillance
• Age ≥ 18 yrs
• Performing less than 15 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report

You may not qualify if…

• Concurrent use of any form of antitumor therapy (endocrine therapy and anti-HER2 antibodies allowed)
• Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes (does not apply to Cohort 5: EDD)
• Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation.
• Mental impairment leading to inability to cooperate
• Any of the following contraindications to cardiopulmonary exercise testing (Cohorts 1 and 2 only):
• Acute myocardial infarction within 3-5 days of any planned study procedures;
• Unstable angina
• Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
• Recurrent syncope
• Active endocarditis
• Acute myocarditis or pericarditis
• Symptomatic severe aortic stenosis
• Uncontrolled heart failure
• Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
• Thrombosis of lower extremities within 3 months of any planned study procedures
• Suspected dissecting aneurysm
• Uncontrolled asthma
• Pulmonary edema
• Respiratory failure
• Acute non-cardiopulmonary disorders that may affect exercise performance
• Room air desaturation at rest ≤ 85% (Cohorts 1 and 2 only)

Where it is running

• University of California, Los Angeles (Data or Specimen Analysis Only) — Los Angeles, California, United States
• SOMALOGIC (Data or Specimen Analysis Only) — Boulder, Colorado, United States
• Memorial Sloan Kettering Monmouth — Middletown, New Jersey, United States
• Memorial Sloan Kettering Bergen — Montvale, New Jersey, United States
• Memorial Sloan Kettering Commack — Commack, New York, United States
• Memorial Sloan Kettering Westchester — Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Nassau — Uniondale, New York, United States
• LABORATORY CORPORATION OF AMERICA HOLDINGS (Data or Specimen Analysis Only) — Burlington, North Carolina, United States
• Duke University Medical Center (Data or Specimen Analysis Only) — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.